Efficacy and safety of pharmacological treatments in inclusion body myositis: a systematic review
Authors' conclusion
Drug interventions for IBM were not effective for most of the outcomes of interest.
Study context
- Population
- Adults with inclusion body myositis (IBM)14 RCTs
- Comparison
- Pharmacological treatments for IBM
- Outcome
- Efficacy (muscle strength, physical function, mobility, muscle trophicity)
Methodological detailsconducted according to the Cochrane Handbook, update of a previous Cochrane review, independent dual-reviewer risk of bias assessment, data extraction and synthesis, 487 records screened, 48 full-text reviewed, 14 included; only 2 RCTs meta-analysed due to clinical heterogeneity
- Conducted according to the Cochrane Handbook
- Update of a previous Cochrane review
- Independent dual-reviewer risk of bias assessment, data extraction and synthesis
- 487 records screened, 48 full-text reviewed, 14 included; only 2 RCTs meta-analysed due to clinical heterogeneity
Pooled result
As reported in the abstract
- Trials of methotrexate (MTX), IV immunoglobulin, interferon beta-1a and MTX, MTX and anti-T-lymphocyte immunoglobulin, oxandrolone, MTX and AZA, bimagrumab, arimoclomol, and sirolimus: low- to high-quality evidence of no effect on IBM progression
Original publication
Efficacy and safety of pharmacological treatments in inclusion body myositis: a systematic review. RMD Open. Published 22 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →